Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

Aller à Demande

1. WO2009077854 - GLUCANES AVEC ADJUVANT

Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

[ EN ]

CLAIMS
What is claimed is:
1. An immunogenic composition comprising: (a) a glucan containing β-l,3-linkages and/or β-1, 6- linkages; and (b) an adjuvant, provided that component (b) is not complete Freund's adjuvant and is not cholera toxin.
2. The composition of claim 1, wherein the glucan is a single molecular species.
3. An immunogenic composition comprising a glucan containing β-l,3-linkages and/or β-l,6-linkages, wherein said glucan is a single molecular species and is conjugated to a carrier protein.
4. The composition of claim 3, wherein the composition further comprises an adjuvant.
5. The composition of claim 1 or claim 2, wherein the glucan is conjugated to a carrier protein.
6. The composition of any one of claims 3 to 5, wherein the glucan is conjugated to the carrier protein directly.
7. The composition of any one of claims claim 3 to 5, wherein the glucan is conjugated to the carrier protein via a linker.
8. The composition of any one of claims 3 to 7, wherein the carrier protein is a bacterial toxin or toxoid, or a mutant thereof.
9. The composition of claim 8, wherein the carrier protein is CRM 197.
10. The composition of any preceding claim, wherein the glucan has a molecular weight of less than 100 kDa (e.g. less than 80, 70, 60, 50, 40, 30, 25, 20, or 15 kDa).
1 1. The composition of any preceding claim, wherein the glucan has 60 or fewer glucose monosaccharide units.
12. The composition of any preceding claim, wherein the glucan is a β-1 ,3 glucan with some β-1 ,6 branching.
13. The composition of claim 12, wherein the glucan is a laminarin.
14. The composition of any preceding claim, wherein the glucan β-1 ,3-iinked glucose residues and β-1 ,6-linked glucose residues, with a ratio of β-1 ,3 linked glucose residues to β-l ,6-linked residues of at least 8: 1 and/or there are one or more sequences of at least five adjacent non-terminal residues linked to other residues only by β-1 ,3 linkages.
15. The composition of claim 13, wherein the glucan comprises both β-1 ,3-linked glucose residues and β-l,6-linked glucose residues, with a ratio of β-1,3 linked glucose residues to β-l,6-linked residues of at least 8: 1.

16. The composition of any preceding claim, wherein the glucan has exclusively β-1,3 linkages.
17. The composition of any one of claims 14 to 16, wherein the glucan is a curdlan.
18. The composition of any preceding claim, including a pharmaceutically acceptable carrier.
19. The composition of any preceding claim, wherein the adjuvant comprises one or more of: an aluminium salt, such as an aluminium hydroxide; an oil-in-water emulsion; an immunostimulatory oligonucleotide; and/or an α-glycosylceramide.
20. The composition of claim 19, wherein the adjuvant comprises an immunostimulatory oligonucleotide and a polycationic oligopeptide.
21. A method for raising an immune response in a mammal, comprising administering to the mammal a composition of any preceding claim.
22. A process for purifying glucan comprising a step of separating phlorotannin from the glucan to produce glucan having a UV absorbance at 270nm of less than 0.17 at 1 mg/ml in water.
23. The process of claim 22, wherein the phlorotannin is separated from the glucan by filtration using a depth filter.
24. The process of claim 22 or claim 23, wherein the process further comprises a subsequent step of measuring the phlorotannin contamination of the glucan.
25. A glucan having a UV absorbance at 270nm of less than 0.17 at 1 mg/ml in water.
26. A glucan obtained by or obtainable by the process of any of claims 22 to 24.
27. A method for making a glucan conjugated to a carrier protein, wherein the step of conjugation is carried out in a phosphate buffer with >10mM phosphate.
28. The method of claim 27, wherein the step of conjugation is carried out in a phosphate buffer with 90-1 1O mM phosphate.
29. The method of claim 28, wherein the glucan is attached to a linker prior to the step of conjugation.

30. The method of claim 29, wherein the free end of the linker comprises an ester group.
31. A conjugate obtained by the method of any one of claims 27 to 30.